tbuckley/cabot-search huggingface dataset:
RICHARD BRIGHT OF GUY'S
Authors: H C CAMERON
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Data modifications to phase I study of suramin.
Authors: K Kobayashi, E E Vokes, N J Vogelzang, M J Ratain
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.9.2623 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8823343 Data modifications to phase I study of suramin. K KobayashixK KobayashiSearch for articles by this author , E E VokesxE E VokesSearch for articles by this author , N J VogelzangxN J VogelzangSearch for articles by this author , M J RatainxM J RatainSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.9.2623 PDF "Data modifications to phase I study of suramin.." Journal of Clinical Oncology, 14(9), pp. 2623–2624© 1996 by American Society of Clinical Oncology
Studies of Various Tests for Malignant Neoplastic Diseases. II. The Gruskin Intradermal Test&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Louise Wiegenstein, M. D., Raymond F. Hain, M. D.
Journal: JNCI Journal of the National Cancer Institute (1951)

Studies of Various Tests for Malignant Neoplastic Diseases. II. The Gruskin Intradermal Test Get access Louise Wiegenstein, M. D., Louise Wiegenstein, M. D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Raymond F. Hain, M. D. Raymond F. Hain, M. D. Department of Pathology, University of Washington School of Medicine, Seattle, Wash. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 4, February 1951, Pages 729–732, https://doi.org/10.1093/jnci/11.4.729 Published: 01 February 1951 Article history Received: 14 September 1950 Published: 01 February 1951
AB1028 Description of a Series of Patients with Childhood Rheumatologic Diseases Assessed in a Transition Unit of an Adult Center
Authors: V. Torrente-Segarra, X. Juanola Roura, J.J. Antόn Lόpez, J.M. Nolla-Solé
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To define the clinical characteristics of patients with childhood Rheumatic diseases who reached a Transition Unit of an Adult Rheumatology Center. <h3>Methods</h3> We reviewed the clinical variables in a series of patients seen in the Service Transition Unit of Rheumatology of a tertiary hospital between January 2013 and December 2014. Patients come from a unit of Pediatric Rheumatology where they are transferred to 18 to that Transition Unit. Patients are evaluated per protocol in a monographic specific agenda at the Rheumatology Department in an adult center. They are assisted in adapting at the characteristics of the new hospital. Patients are seen by the Transition Unit for 2 years and then controlled as usual successive visits Rheumatology Department. Both the pediatric center and initially in the adult center, patients are assessed by a specialist Rheumatology Pediatric Rheumatologist. The variables included in this study are: age, diagnosis, presence of clinical activity at the time of the transfer, antirheumatic use of disease-modifying drugs (DMARDs) and use of biological therapy. <h3>Results</h3> We have attended a total of 45 patients during the period described. All were 18 years old at the time of transfer. The diagnoses of patients were: Juvenile Idiopathic Arthritis (JIA) oligoarticular-10 cases (22.2%), JIA associated with enthesitis 7 cases (15.5%), Lupus Erythematosus 4 patients (8.8%), Sd autoinflammatory 3 patients, polyarticular JIA, extended oligoarticular JIA, Juvenile Dermatomyositis, Osteoporosis and Morfea 2 cases each and systemic onset JIA, psoriatic JIA, Sd Sjögren, Mixed Connective Tissue disease, Behçet9s Disease, Rheumatic Fever and JIA undifferentiated 1 case each. At the time of the transfer, 22 patients (48.8%) were treated with DMARDs (methotrexate, leflunomide, hydroxychloroquine, azathioprine) and 14 patients (31.1%) were on biological therapy (7 adalimumab, etanercept June 1 tocilizumab). A total of 8 patients (17.7%) had clinical activity at the time of the change from pediatric to adult hospital. <h3>Conclusions</h3> Transition Unit has enabled us to control a large group of patients with Rheumatic diseases that start in childhood, with a wide range of entities. The complexity of many treatments and disease activity at the time of transfer showed the usefulness of said units in specialized centers. <h3>Disclosure of Interest</h3> None declared
SP0067 What is New in Sjogren's Syndrome
Authors: W.-F. Ng
Journal: Annals of the Rheumatic Diseases (2015)

The “What is New” in Sjögren9s Syndrome (SS) lecture will provide a comprehensive update on the new developments in SS research in the preceding 12 months. The update will include work that has been published in peer-review journals and selected abstracts from major conferences including the EULAR 2015. The lecture will be broadly divided into 3 main themes. 1. Scientific advances in our understanding of the pathogenesis of SS and SS-associated lymphoma. 2. Advances in clinical research in SS including outcome measures and registries. 3. Data from clinical trials of novel therapies in SS. <h3>Disclosure of Interest</h3> None declared
Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
Authors: Joseph M. Flynn, John C. Byrd, Thomas J. Kipps, Michael Boxer, Kathryn S. Kolibaba, Nicola Tyson, Jamie H. Hirata, Jeff Porter Sharman
Journal: Journal of Clinical Oncology (2014)

7083 Background: Early phase 1/2 trials with GA101 in CLL demonstrated single-agent activity with suggestion of a dose response. GAGE (NCT01414205) is a multicenter, randomized study that evaluated GA101 at 2 doses in patients (pts) with symptomatic, untreated CLL. Methods: Randomization of 80 pts with intact organ function and ECOG PS <3 were stratified based on Rai stage (1–2 vs 3–4) and tumor mass (single lesion by CT scan, <5 cm vs ≥5 cm): GA101 1,000 mg (100 mg IV d1, 900 mg d2, 1000 mg d8, d15 of cycle 1; 1000 mg d1 of cycles 2–8) or 2000 mg (100 mg IV d1, 900 mg d2, 1,000 mg d3, 2,000 mg d8, d15 of cycle 1; 2,000 mg d1 of cycles 2–8). Each cycle was 21 days. ORR was assessed at 2 months post-therapy according to the International Workshop on CLL (iwCLL) criteria. Pts had similar pre-treatment demographics in the 2 arms. Median age was 67 (34–91) years, 36% women, 41% Rai stage 3-4, 29% with tumor masses ≥5 cm, 54% unmutated IGHV, and 10% del(17p13). Median follow-up was 11 months. Results: Key efficacy and safety results are shown in table below. Most frequent adverse event (AE) was infusion-related reactions (IRRs). No Grade (Gr) 3/4 IRRs occurred after cycle 1. A death (myocardial infarction) occurred after cycle 5, judged by site investigator as unrelated to GA101. Conclusions: These results demonstrated single-agent efficacy of GA101 at 1,000- and 2,000-mg doses, with a difference in ORR between the 2 arms (P = .08). No new safety signals were observed. Incidences of Gr 3/4 AEs were similar in each arm, except for IRRs. Further study is warranted to determine durability of response and long-term side effects of GA101. Clinical trial information: NCT01414205. Total N = 80 1,000 mg (n = 41) 2,000 mg (n = 39) ORRa, n (%) 20 (49) 26 (67) P value .08b CR/CRi, n (%) 2 (5) 8 (21) SD, n (%) 11 (27) 9 (23) PD, n (%) 3 (7) 0 (0) Unable to evaluate/missingc, n (%) 7 (17) 4 (10) Gr 3-4 AE, % IRR Neutropenia Infections 23 33 3 11 34 5 aORR based on investigator-reported end-of-treatment response, which includes CT scan performed 51+ days from last GA101 dose bPvalue is 2-sided, based on stratified Cochran-Mantel-Haenszel test on ORR cPts classified as missing if no post-baseline response assessments were available or all post-baseline response assessment were performed <51 days from last GA101 dose.
Variability in Amyotrophic Lateral Sclerosis
Authors: Nathan P. Staff
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Predictors of relapse into major depressive disorder in a nonclinical population
Authors: W Coryell, J Endicott, M B Keller
Journal: American Journal of Psychiatry (1991)

This study sought to describe, the natural history of major depressive disorder in a large group of nonclinical subjects. In particular, the analysis determined demographic and clinical risk factors for the recurrence of major depressive disorder.Relatives, comparison subjects (matched to relatives for age and sex), and spouses of affectively ill probands underwent structured clinical assessments before and after a 6-year interval.Of 396 individuals who had had only major depressive disorder that ended before the initial evaluation, 33.8% (N = 134) developed a new episode during the 6-year follow-up period. Youth, but not sex, was an important demographic risk factor. The presence of minor depression at the time of initial evaluation and the number of symptoms recalled from the worst previous episode were additional clinical risk factors. At the initial evaluation, 200 other subjects had described a previous history of both major depressive disorder and a nonaffective mental disorder. When compared to the subjects who recalled only a history of major depressive disorder, these subjects were more likely to have been in an episode of chronic intermittent depression at the initial evaluation and to recall a greater number of episodes as well as a greater number of symptoms in the worst episode. A history of a nonaffective mental disorder significantly increased the risk of relapse into major depressive disorder.These findings agree well with a recent review of clinically based follow-up studies. Thus, youth and a history of nonaffective illness are important risk factors for the recurrence of major affective disorder in a broad variety of settings.
Spectrum of Breast Disease in Outpatient Surgical Practice
Authors: P J Cox, M K W Li, H Ellis
Journal: Journal of the Royal Society of Medicine (1982)

Seven hundred and fifty-three new referrals with problems relating to the breast were seen as outpatients in a general surgical clinic during 1980 and 1981. The age distribution and final diagnoses are reported with a breakdown into the varying pathological groups. The relationship of diagnosis to previous benign breast disease, parity and breastfeeding is discussed.
The Diagnosis of Stupor and Coma
Authors: Charles M. Poser
Journal: JAMA (1981)

The new, third edition of this classic is almost 100 pages longer than the previous one and represents what one could well call a textbook of diseases of the brain (as opposed to the rest of the nervous system). Such a title might be more appropriate. The authors must have found it extremely difficult to resist the temptation to achieve an exhaustive review of all conditions, even some of the most exotic and unusual, that may, on rare occasion, lead to stupor or coma. This successful endeavor to be comprehensive carries an inherent danger: it might frighten the physicians most likely to benefit from the book's frequent perusal, such as house officers, family practitioners, and emergency room physicians who will unquestionably and understandably be most concerned with the "how-to" portions of the volume, particularly since they are so clearly written and exquisitely instructive. The authors state that one of the
Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial
Authors: Jose M Álvaro-Gracia, Juan A Jover, Rosario García-Vicuña, Luis Carreño, Alberto Alonso, Sara Marsal, Francisco Blanco, Victor M Martínez-Taboada, Peter Taylor, Cristina Martín-Martín, Olga DelaRosa, Ignacio Tagarro, Federico Díaz-González
Journal: Annals of the Rheumatic Diseases (2016)

To evaluate the safety and tolerability of the intravenous administration of Cx611, a preparation of allogeneic expanded adipose-derived stem cells (eASCs), in patients with refractory rheumatoid arthritis (RA), as well as to obtain preliminary clinical efficacy data in this population.It is a multicentre, dose escalation, randomised, single-blind (double-blind for efficacy), placebo-controlled, phase Ib/IIa clinical trial. Patients with active refractory RA (failure to at least two biologicals) were randomised to receive three intravenous infusions of Cx611: 1 million/kg (cohort A), 2 million/kg (cohort B), 4 million/kg (cohort C) or placebo, on days 1, 8 and 15, and they were followed for therapy assessment for 24 weeks.Fifty-three patients were treated (20 in cohort A, 20 in cohort B, 6 in cohort C and 7 in placebo group). A total of 141 adverse events (AEs) were reported. Seventeen patients from the group A (85%), 15 from the group B (75%), 6 from the group C (100%) and 4 from the placebo group (57%) experienced at least one AE.Eight AEs from 6 patients were grade 3 in intensity (severe), 5 in cohort A (lacunar infarction, diarrhoea, tendon rupture, rheumatoid nodule and arthritis), 2 in cohort B (sciatica and RA) and 1 in the placebo group (asthenia). Only one of the grade 3 AEs was serious (the lacunar infarction). American College of Rheumatology 20 responses for cohorts A, B, C and placebo were 45%, 20%, 33% and 29%, respectively, at month 1, and 25%, 15%, 17% and 0%, respectively, at month 3.The intravenous infusion of Cx611 was in general well tolerated, without evidence of dose-related toxicity at the dose range and time period studied. In addition, a trend for clinical efficacy was observed. These data, in our opinion, justify further investigation of this innovative therapy in patients with RA.EudraCT: 2010-021602-37; NCT01663116; Results.
Sex differences in age at first hospital admission for schizophrenia: fact or artifact?
Authors: R R Lewine, J S Strauss, T E Gift
Journal: American Journal of Psychiatry (1981)

Reports that men develop schizophrenia earlier than women could be a clue to major factors in the pathological processes of schizophrenia or they could be diagnostic artifacts. The authors evaluated the effect of alternative diagnostic systems on age at first admission for schizophrenia, depression, and personality disorder. They found that the age-sex disproportion is specific to schizophrenia and occurs irrespective of the diagnostic system. An unexpected relationship between diagnostic system and sex differences in the rate of schizophrenia obtained, however: the broadest and narrowest sets of criteria yielded approximately equal proportions of females and males, but intermediate systems yielded a significantly greater proportion of males than females.
PTU-013 Is endoscopic full-thickness resection feasible and safe in the colon?
Authors: A Currie, R Tarquini, A Brigic, R Kennedy
Journal: Gut (2015)

<h3>Introduction</h3> Colectomy for complex colonic polyps and early colonic cancer has increased due to national bowel cancer screening programs. However, traditional radical colonic resection risks substantial morbidity and alternative approaches are required. This review summarises the published methods of colonic endoscopic full-thickness resection (EFTR), examining data on feasibility and safety. <h3>Method</h3> Systematic literature searches identified articles describing EFTR techniques of colon, published between 1990 and 2015 in both experimental and clinical studies. Feasibility and safety were the primary outcomes. <h3>Results</h3> Preclinical research reported on three EFTR techniques using endoscopic stapling devices, T-tags or compression device closure for defect closure before (pre-resection) or after specimen resection (post-resection). A total of 103 procedures were performed in 99 porcine models, with an overall success rate of 87% (90/103 procedures). The intraoperative complication rate was 19% (17/90 procedures). Post-resection closure methods more commonly resulted in failure to close the defect and a high incidence of abnormal findings at post-mortem examination. Five clinical studies reported EFTR in 38 patients, with three studies using a compression device for pre-resection closure and one study reporting a post-resection closure technique. EFTR was completed in 33/38 patients without assistance. Only three patients had reported complications. Lateral margin clearance was variably reported and complete full-thickness resection was achieved in only 12/17 patients. <h3>Conclusion</h3> The technique of EFTR is evolving, with only limited clinical evidence to date, but currently pre-resection closure methods should be advocated. Significant technological challenges remain before colonic EFTR can be recommended in clinical practice, including reproducible lateral margin clearance. <h3>Disclosure of interest</h3> None Declared.
Follow-up study of 11 patients with potentially reversible tardive dyskinesia
Authors: G Yagi, H Itoh
Journal: American Journal of Psychiatry (1987)

The authors followed the course of 11 patients with potentially reversible tardive dyskinesia while they were taking minimum effective neuroleptic doses. After 10 years, the symptoms of tardive dyskinesia had disappeared in eight patients, were minimal or questionable in one, and had become persistent in two.
Emergence of a novel cluster of influenza A(H5N1) virus clade 2.2.1.2 with putative human health impact in Egypt, 2014/15
Authors: A S Arafa, M M Naguib, C Luttermann, A A Selim, W H Kilany, N Hagag, A Samy, A Abdelhalim, M K Hassan, E M Abdelwhab, Y Makonnen, G Dauphin, J Lubroth, T C Mettenleiter, M Beer, C Grund, T C Harder
Journal: Eurosurveillance (2015)

A distinct cluster of highly pathogenic avian influenza viruses of subtype A(H5N1) has been found to emerge within clade 2.2.1.2 in poultry in Egypt since summer 2014 and appears to have quickly become predominant. Viruses of this cluster may be associated with increased incidence of human influenza A(H5N1) infections in Egypt over the last months.
AB0889 Massive Elimination of Multinucleated Osteoclasts by Eupatilin is Due to Dual Inhibition of Transcription and Cytoskeletal Rearrangement
Authors: J.-M. Baek, W.-S. Lee, W.-H. Yoo, J.-Y. Kim, J.-M. Oh, M.-S. Lee, C.-H. Lee
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Osteoporosis is an ageing-associated diseases requiring better therapeutic modality. Eupatilin is a major flavonoid from Artemisia. <h3>Objectives</h3> We aimed to evaluate the effects of eupatilin on RANKL-induced osteoclast differentiation and its mechanism of action. <h3>Results</h3> Upon stimulation prior to nuclear factor κB (RANK)-ligand (RANKL) treatment or poststimulation of bone marrow macrophages (BMCs) in the presence of RANKL with eupatilin complete blockade of RANK-dependent osteoclastogenesis was accomplished. This blockade was accompanied by inhibition of rapid phosphorylation of <i>Akt, GSK3b</i>, <i>ERK</i> and <i>IkB</i> as well as downregulation of c-Fos and NFATc1 at protein levels, suggesting that transcriptional suppression is a key acting mechanism on the anti-osteoclastogenesis. Transient reporter assays or gain of function assays confirmed that eupatilin was, indeed, a potent transcriptional inhibitor in osteoclasts (OC). Surprisingly, when multinucleated osteoclasts (MNCs) were cultured on bone scaffolds in the presence of eupatilin bone resorption activity was also completely blocked by dismantling actin ring, suggesting that another major acting site of eupatilin is cytoskeletal rearrangement. The eupatilin-treated MNCs revealed a shrunk cytoplasm and accumulation of multi-nuclei, eventually becoming fibroblast-like cells. No apoptosis occurred. Inhibition of phosphorylation of <i>cofilin</i> by eupatilin suggests that actin may play an important role in the catastrophic morphological change of MNCs. Human OC were similarly responded to eupatilin. When eupatilin was administered to LPS-induced osteoporotic mice after manifestation of osteoporosis, it was capable of preventing bone loss. The ovariectomized (OVX) mice remarkably exhibited bone protection effects. <h3>Conclusions</h3> Taken together, eupatilin is an effective versatile therapeutic intervention for osteoporosis as dual blockaders; 1) transcriptional suppression of c-Fos and NFATc1 of differentiating OC and 2) inhibition of actin rearrangement of pathogenic MNCs. <h3>Disclosure of Interest</h3> None declared